Positively Aware Baraclude HBV

Baraclude

entecavir, or ETV

 
Nucleoside "Nuke"

Standard Dose

Adult (age 16 and older): Treatment-naïve with no known or suspected resistance, one 0.5 mg tablet once daily. If lamivudine refractory (did not achieve adequate results) or lamivudine or telbivudine (brand name Tyzeka, discontinued for use since December 2016) resistant, one 1 mg tablet once daily. Decompensated liver disease: one 1 mg once per day. Baraclude should always be taken on an empty stomach (no food 2 hours before or 2 hours after taking pill). Dose adjustments needed for individuals with kidney disease and CrCl less than 50 mL/min. See drug page and consult a medical provider for more details.

Pediatric (age 2–15, weighing at least 10 kg): Weight-based dosing, which is complicated and should be managed in consultation with an experienced medical provider, is required. Baraclude is available as an oral solution (liquid) and can be used in children up to 30 kg.

Manufacturer

Bristol-Myers Squibb

AWP

brand: 0.5 mg and 1 mg tablets: $1,647 / month
generic: 0.5 mg and 1 mg tablets: $216–$1,800 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information